Consumer Test-Launch of SIGRID's Glucose Stabiliser proves major success

Over 91% of U.S. and Swedish customers surveyed report that the 100% natural GLP-1 companion product provides more stable glucose levels, reduces bloating, and curbs the urge to snack

STOCKHOLM, SWEDEN — January 7th, 2025 — SIGRID Therapeutics, the innovative health tech company revolutionizing metabolic health, has successfully completed the test-launch phase for its groundbreaking dietary supplement, Glucose Stabiliser. This achievement underscores the product's immense commercial potential, fueled by strong market demand and exceptional customer retention.

Since launching in the U.S. and Sweden via direct-to-consumer (DTC) e-commerce platforms, SIGRID has sold 6,600 bottles of Glucose Stabiliser at a retail price of $89, achieving net profitability during the test phase. The product's unique benefits, including regulating blood sugar, supporting weight management, boosting energy, and reducing bloating, have resonated strongly with consumers. Many users are transitioning from GLP-1 medications to Glucose Stabiliser to sustain weight loss after reaching their goals, establishing it as a supportive GLP-1 companion product.

A Strong Commercial Proof of Concept

The test-launch has yielded exceptional metrics:

• High Willingness to Pay: Average net selling price exceeded $75 after discounts.
• Efficient Conversion Rates: Over 4% of acquired traffic converted into paying customers.
• High Lifetime Value (LTV): Each new subscriber boasts an LTV of over $250.
• Cost-Effective Customer Acquisition: Maintained a Customer Acquisition Cost (CAC) of under $100 through paid digital advertising.

Subscription Model Success

In March, SIGRID introduced a subscription program in the U.S., offering a 22% discount for monthly deliveries. Results highlight customer loyalty and satisfaction with Glucose Stabiliser:

• Approximately 70% of new customers opted for subscription plans.
• Over 600 customers enrolled, with an impressive 65% retention rate after one month and 30% retention at six months.

Proven Customer Benefits

Recent customer surveys confirm Glucose Stabiliser’s effectiveness, reflecting its powerful impact on metabolic health and well-being:

• 91% reported more stable blood sugar levels.
• 93% felt fuller for longer, while 89% experienced a reduced urge to snack.
• 92% reported less bloating after meals.

Endorsements Drive Engagement

Glucose Stabiliser has received endorsements from renowned physicians and health advocates as well as integrative nutrition diabetes health coaches in the U.S. and Sweden. These experts have shared their Continuous Glucose Monitor (CGM) data while using the product with their followers, sparking widespread engagement and driving sales. Their support underscores the trustworthiness and effectiveness of the product.

Scaling for Growth

These achievements were realized with a lean team and limited marketing budget, showcasing the strength of SIGRID’s operational model. To support rapid growth, SIGRID is now:

• Scaling Winning Marketing Tactics: Increasing investment in high-performing campaigns while diversifying its approach.
• Enhancing Customer Loyalty Ecosystem: Introducing new initiatives to further boost retention and engagement.
• Building Strategic Partnerships: Collaborating with key influencers and thought leaders to expand brand reach.
• Improving Operational Efficiency: Optimizing supply chains and processes to support increased demand.

CEO Sana Alajmovic commented, “We are thrilled with the results of our test-launch and the overwhelming consumer reception for Glucose Stabiliser. Nearly all of the consumers surveyed were delighted with its multiple positive health effects. With a robust supply chain in place and growing interest from pharmacies and clinics, we are well-positioned to scale and meet increasing demand. This milestone underscores the strength of our scientifically developed solution and its ability to meet the growing demand for safe and effective, non-invasive metabolic health solutions.”

For more information, visit www.sigridstabiliser.com

Media Contact:

Ola Björkman, ola@rhacomms.eu

About Glucose Stabiliser

Glucose Stabiliser, powered by patented SiPore® technology, is a 100% natural solution that regulates blood sugar and reduces caloric intake from fats and carbs by working locally in the gut. Its non-systemic nature ensures unparalleled safety and efficacy. Developed over 13 years of rigorous research, SiPore® technology is backed by clinical evidence, highlighting its potential to transform metabolic health for diabetics and non-diabetics alike.

About SIGRID Therapeutics:

SIGRID Therapeutics is a Sweden-based healthtech company dedicated to revolutionizing metabolic health through cutting-edge, science-backed innovations. Its flagship product, Glucose Stabiliser, is powered by patented SiPore® technology, offering a safe, effective, and natural way to regulate blood sugar and support weight management.